2023
So Now We Know—Reflections on the Extent of Resection for Stage I Lung Cancer
Detterbeck F, Ely S, Udelsman B, Blasberg J, Boffa D, Dhanasopon A, Mase V, Woodard G. So Now We Know—Reflections on the Extent of Resection for Stage I Lung Cancer. Clinical Lung Cancer 2023, 25: e113-e123. PMID: 38310034, DOI: 10.1016/j.cllc.2023.12.007.Peer-Reviewed Original ResearchStage I lung cancerI lung cancerSublobar resectionRecurrence-free survivalHealthy patientsLung cancerRecent trialsInadequate resection marginsLarge recent trialsAdditional randomized trialsHigh-level evidenceOverall survival differenceExtent of resectionLong-term outcomesLong-term resultsHigh locoregional recurrenceAspects of patientsLesser resectionsLocoregional recurrencePerioperative morbidityIntraoperative detailsLung functionResection extentResection marginsPostoperative changesImpact of the COVID-19 Pandemic on Lung Cancer Screening Processes in a Northeast Tertiary Health Care Network
Udelsman B, Detterbeck F, Tanoue L, Mase V, Boffa D, Blasberg J, Dhanasopon A, Ely S, Mazzarelli L, Bader A, Woodard G. Impact of the COVID-19 Pandemic on Lung Cancer Screening Processes in a Northeast Tertiary Health Care Network. Journal Of Computer Assisted Tomography 2023, 48: 222-225. PMID: 37832536, DOI: 10.1097/rct.0000000000001549.Peer-Reviewed Original ResearchHealth care networkLung cancer screening processLung cancer screening programsCare networkCancer screening programsCoronavirus disease 2019 (COVID-19) pandemicComputed tomography scanCOVID-19 hospitalizationCOVID-19 surgeCancer screening processDisease 2019 pandemicLung cancer diagnosisHealth care systemAverage hospitalizationRadiology databaseLung cancerTomography scanScreening programCare systemCancer diagnosisMonthsHospitalizationCOVID-19COVID-19 pandemicPandemicBrief Report: Increasing Prevalence of Ground-Glass Nodules and Semisolid Lung Lesions on Outpatient Chest Computed Tomography Scans
Woodard G, Udelsman B, Prince S, Blasberg J, Dhanasopon A, Gange C, Traube L, Mase V, Boffa D, Detterbeck F, Bader A. Brief Report: Increasing Prevalence of Ground-Glass Nodules and Semisolid Lung Lesions on Outpatient Chest Computed Tomography Scans. JTO Clinical And Research Reports 2023, 4: 100583. PMID: 38074773, PMCID: PMC10709040, DOI: 10.1016/j.jtocrr.2023.100583.Peer-Reviewed Original ResearchGround-glass nodulesChest CT scanCT scanLung lesionsHealth systemLarge academic health systemAcademic health systemCross-sectional imagingRadiographic findingsPhysician consultationChest CTDatabase reviewTomography scanRadiographic lesionsAge groupsLesionsStudy periodLung nodulesOutpatient CTRadiology reportsAdult chestCTScansChestNodulesOverall survival in low-comorbidity patients with stage I non–small cell lung cancer who chose stereotactic body radiotherapy compared to surgery
Udelsman B, Canavan M, Zhan P, Ely S, Park H, Boffa D, Mase V. Overall survival in low-comorbidity patients with stage I non–small cell lung cancer who chose stereotactic body radiotherapy compared to surgery. Journal Of Thoracic And Cardiovascular Surgery 2023, 167: 822-833.e7. PMID: 37500052, DOI: 10.1016/j.jtcvs.2023.07.021.Peer-Reviewed Original ResearchNon-small cell lung cancerStereotactic body radiotherapyStage I non-small cell lung cancerLow-comorbidity patientsCell lung cancerOverall survivalSurgical managementLung cancerSurgical resectionBody radiotherapyClinical stage I non-small cell lung cancerEarly-stage non-small cell lung cancerPropensity score-matched cohortPropensity score-matched patientsPropensity score-matched analysisEarly-stage lung cancerLong-term OSNational Cancer DatabaseProportion of patientsCancer DatabasePatientsSBRT patientsSurgeryCancerMortalityPP01.12 Increasing Diagnosis of Ground Glass Nodules and Semi-Solid Lung Lesions on Chest CT Scans over the Past Decade
Woodard G, Tanoue L, Detterbeck F, Boffa D, Mase V, Blasberg J, Dhanasopon A, Gosangi B, Traube L, Bader A. PP01.12 Increasing Diagnosis of Ground Glass Nodules and Semi-Solid Lung Lesions on Chest CT Scans over the Past Decade. Journal Of Thoracic Oncology 2023, 18: e15. DOI: 10.1016/j.jtho.2022.09.038.Peer-Reviewed Original ResearchThe evidence behind lung cancer screening: a narrative review of randomized clinical trials
Mase V, Kumbasar U, Detterbeck F. The evidence behind lung cancer screening: a narrative review of randomized clinical trials. Current Challenges In Thoracic Surgery 2023, 0: 0-0. DOI: 10.21037/ccts-21-30.Peer-Reviewed Original Research
2022
Surgical Management of Pneumothorax and Pleural Space Disease
Dhanasopon AP, Blasberg JD, Mase VJ. Surgical Management of Pneumothorax and Pleural Space Disease. Surgical Clinics Of North America 2022, 102: 413-427. PMID: 35671764, DOI: 10.1016/j.suc.2022.03.001.Peer-Reviewed Original ResearchA guide for managing patients with stage I NSCLC: deciding between lobectomy, segmentectomy, wedge, SBRT and ablation— part 1: a guide to decision-making
Detterbeck FC, Blasberg JD, Woodard GA, Decker RH, Kumbasar U, Park HS, Mase VJ, Bade BC, Li AX, Brandt WS, Madoff DC. A guide for managing patients with stage I NSCLC: deciding between lobectomy, segmentectomy, wedge, SBRT and ablation— part 1: a guide to decision-making. Journal Of Thoracic Disease 2022, 0: 0-0. PMID: 35813719, PMCID: PMC9264102, DOI: 10.21037/jtd-21-1823.Peer-Reviewed Original ResearchLong-term outcomesIndividual patientsHealthy patientsLung cancerFavorable tumorsStage I lung cancerBetter long-term outcomesI lung cancerStage I NSCLCOlder patientsPatient selectionPoint of careSurgical approachClinical careEffect modifiersTreatment selectionPatientsTreatment approachesPatient valuesClinical judgmentSystematic reviewRelevant outcomesLong-term differencesAvailable evidenceShort-term differencesA guide for managing patients with stage I NSCLC: deciding between lobectomy, segmentectomy, wedge, SBRT and ablation—part 2: systematic review of evidence regarding resection extent in generally healthy patients
Detterbeck FC, Mase VJ, Li AX, Kumbasar U, Bade BC, Park HS, Decker RH, Madoff DC, Woodard GA, Brandt WS, Blasberg JD. A guide for managing patients with stage I NSCLC: deciding between lobectomy, segmentectomy, wedge, SBRT and ablation—part 2: systematic review of evidence regarding resection extent in generally healthy patients. Journal Of Thoracic Disease 2022, 0: 0-0. PMID: 35813747, PMCID: PMC9264068, DOI: 10.21037/jtd-21-1824.Peer-Reviewed Original ResearchNon-randomized comparisonHealthy patientsResection extentIndividual patientsSystematic reviewStage I lung cancerI lung cancerStage I NSCLCCharacteristics of patientsPulmonary function testsLong-term outcomesRisk of recurrenceVideo-assisted approachSublobar resectionWedge resectionRandomized trialsFunction testsLung cancerResidual confoundingEffect modifiersShort-term benefitsLobectomyPatientsPubMed systematic reviewMargin distanceA guide for managing patients with stage I NSCLC: deciding between lobectomy, segmentectomy, wedge, SBRT and ablation—part 3: systematic review of evidence regarding surgery in compromised patients or specific tumors
Bade BC, Blasberg JD, Mase VJ, Kumbasar U, Li AX, Park HS, Decker RH, Madoff DC, Brandt WS, Woodard GA, Detterbeck FC. A guide for managing patients with stage I NSCLC: deciding between lobectomy, segmentectomy, wedge, SBRT and ablation—part 3: systematic review of evidence regarding surgery in compromised patients or specific tumors. Journal Of Thoracic Disease 2022, 0: 0-0. PMID: 35813753, PMCID: PMC9264070, DOI: 10.21037/jtd-21-1825.Peer-Reviewed Original ResearchLimited pulmonary reserveLong-term outcomesResection extentNon-randomized comparisonPulmonary reserveOlder patientsIndividual patientsFavorable tumorsSystematic reviewStage I lung cancerFavorable long-term outcomeI lung cancerScreen-detected tumorsStage I NSCLCCharacteristics of patientsShort-term outcomesLesser resectionsPerioperative mortalityPulmonary functionSublobar resectionWedge resectionPatient selectionRandomized trialsLung cancerResidual confoundingA guide for managing patients with stage I NSCLC: deciding between lobectomy, segmentectomy, wedge, SBRT and ablation—part 4: systematic review of evidence involving SBRT and ablation
Park HS, Detterbeck FC, Madoff DC, Bade BC, Kumbasar U, Mase VJ, Li AX, Blasberg JD, Woodard GA, Brandt WS, Decker RH. A guide for managing patients with stage I NSCLC: deciding between lobectomy, segmentectomy, wedge, SBRT and ablation—part 4: systematic review of evidence involving SBRT and ablation. Journal Of Thoracic Disease 2022, 0: 0-0. PMID: 35813762, PMCID: PMC9264060, DOI: 10.21037/jtd-21-1826.Peer-Reviewed Original ResearchLong-term outcomesNon-randomized comparisonIndividual patientsSystematic reviewStage I lung cancerI lung cancerCharacteristics of patientsStage I NSCLCPulmonary function testsMinority of patientsShort-term outcomesStereotactic body radiotherapyThermal ablationLate toxicityPulmonary functionRandomized trialsFunction testsAdjusted comparisonsBody radiotherapyLung cancerResidual confoundingEffect modifiersShort-term benefitsPatientsPubMed systematic reviewAssociation Between Food and Drug Administration Approval and Disparities in Immunotherapy Use Among Patients With Cancer in the US
Ermer T, Canavan ME, Maduka RC, Li AX, Salazar MC, Kaminski MF, Pichert MD, Zhan PL, Mase V, Kluger H, Boffa DJ. Association Between Food and Drug Administration Approval and Disparities in Immunotherapy Use Among Patients With Cancer in the US. JAMA Network Open 2022, 5: e2219535. PMID: 35771575, PMCID: PMC9247736, DOI: 10.1001/jamanetworkopen.2022.19535.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerRenal cell carcinomaUse of immunotherapyFDA approvalImmunotherapy useCohort studyClinical trialsNovel therapiesStage IV non-small cell lung cancerMultivariable logistic regression modelingFirst checkpoint inhibitorCheckpoint inhibitor therapyNational Cancer DatabasePatients 20 yearsCell lung cancerSocioeconomic strataTreatment of patientsDrug Administration approvalLife-saving treatmentReceipt of immunotherapyLogistic regression modelingSocioeconomic characteristicsImmunotherapy administrationCheckpoint inhibitorsPatient characteristicsRevisiting Indications for Brain Imaging During the Clinical Staging Evaluation of Lung Cancer
Pichert MD, Canavan ME, Maduka RC, Li AX, Ermer T, Zhan PL, Kaminski M, Udelsman BV, Blasberg JD, Mase VJ, Dhanasopon AP, Boffa DJ. Revisiting Indications for Brain Imaging During the Clinical Staging Evaluation of Lung Cancer. JTO Clinical And Research Reports 2022, 3: 100318. PMID: 35540711, PMCID: PMC9079298, DOI: 10.1016/j.jtocrr.2022.100318.Peer-Reviewed Original ResearchPrevalence of brainBrain metastasesSummary stageBrain imagingN classificationIsolated brain metastasesNode-negative NSCLCRoutine brain imagingStage II NSCLCStage IV NSCLCClinical stage INational Cancer DatabaseEarly-stage NSCLCStage IAStage IIIAStage NSCLCStaging evaluationClinical stageLung cancerCancer DatabaseN stageNSCLCPatientsStage IMetastasisComparing a Novel Hand-Held Device for Chest Tube Insertion to the Traditional Open Tube Thoracostomy for Simple Pneumothorax in a Porcine Model.
Dilday J, Heidenreich B, Spitzer H, Abuhakmeh Y, Ahnfeldt E, Watt J, Mase V. Comparing a Novel Hand-Held Device for Chest Tube Insertion to the Traditional Open Tube Thoracostomy for Simple Pneumothorax in a Porcine Model. Journal Of Special Operations Medicine 2022, 22: 41-45. PMID: 36525010, DOI: 10.55460/sh55-ifp6.Peer-Reviewed Original ResearchConceptsVideo-Assisted Thoracoscopic SurgeryChest tube insertionTube thoracostomyOpen thoracostomyPneumothorax resolutionTube insertionSimple pneumothoraxInjury ratesTreatment of pneumothoraxAssisted Thoracoscopic SurgeryInsertion timeNovel hand-held deviceBlood lossThoracoscopic surgeryChest tubeCommon injuriesIatrogenic injuryTube placementNeedle decompressionPneumothorax managementTension pneumothoraxVisceral pleuraEffective treatmentThoracostomyPneumothorax
2021
Formal Military Civilian Affiliations Are a Template for Low Military Cardiothoracic Surgery Volume
DeBarros M, Jaklitsch M, Bueno R, Mase VJ. Formal Military Civilian Affiliations Are a Template for Low Military Cardiothoracic Surgery Volume. The Annals Of Thoracic Surgery 2021, 114: 621-624. PMID: 34597685, DOI: 10.1016/j.athoracsur.2021.08.055.Peer-Reviewed Original Research
2019
Can the Centers for Medicare and Medicaid Star Ratings Be Used as a Realistic Approach to Reduce Mortality in Complex Cancer Surgery?
Papageorge M, Hoag J, Resio B, Monsalve A, Pathak R, Mase V, Dhanasopon A, Blasberg J, Boffa D. Can the Centers for Medicare and Medicaid Star Ratings Be Used as a Realistic Approach to Reduce Mortality in Complex Cancer Surgery? Journal Of The American College Of Surgeons 2019, 229: s144. DOI: 10.1016/j.jamcollsurg.2019.08.319.Peer-Reviewed Original Research
2018
Quality of Thoracic Lymph Node Evaluation in the Department of Defense According to the American College of Surgeons Commission on Cancer Surveillance Measure: Is There a Survival Benefit?
Heidenreich B, Durkee A, Bader J, Ahnfeldt E, Mase V. Quality of Thoracic Lymph Node Evaluation in the Department of Defense According to the American College of Surgeons Commission on Cancer Surveillance Measure: Is There a Survival Benefit? Journal Of The American College Of Surgeons 2018, 227: s185. DOI: 10.1016/j.jamcollsurg.2018.07.395.Peer-Reviewed Original Research
2010
Admission physiology criteria upon presentation to combat support hospitals; are current critical vital signs effective?
Mase V, Baer D, Wade C, Eastridge B, Walters T. Admission physiology criteria upon presentation to combat support hospitals; are current critical vital signs effective? Journal Of The American College Of Surgeons 2010, 211: s106. DOI: 10.1016/j.jamcollsurg.2010.06.280.Peer-Reviewed Original ResearchEffect of skeletal muscle ischemia‐reperfusion (I/R) postconditioning (Post C) on antioxidant status in rats
Dubick M, Mase V, Barr J, Grubbs D, Roe J, Walters T. Effect of skeletal muscle ischemia‐reperfusion (I/R) postconditioning (Post C) on antioxidant status in rats. The FASEB Journal 2010, 24: 591.3-591.3. DOI: 10.1096/fasebj.24.1_supplement.591.3.Peer-Reviewed Original ResearchThiobarbituric acid reactive substancesAntioxidant statusC musclesTotal nitric oxide levelsAntioxidant enzyme activitiesNitric oxide levelsContralateral control musclesXanthine oxidaseAcid reactive substancesTotal antioxidant potentialMyeloperoxidase activityMuscle damageXO activityOxide levelsControl musclesMuscle lossNitric oxideRatsBattlefield mortalitySkeletal muscleReactive substancesMuscleAntioxidant potentialEnzyme activityPresent study